Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Håkon Reikvam, Tuyen Thi van Hoang & Øystein Bruserud. (2015) Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets. Expert Review of Hematology 8:3, pages 315-327.
Read now
Read now
Håkon Reikvam, Michelle Hauge, Annette K Brenner, Kimberley Joanne Hatfield & Øystein Bruserud. (2015) Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) – gene transcription, cell cycle regulation, metabolism and intercellular communication. Expert Review of Hematology 8:3, pages 299-313.
Read now
Read now
Alice C Fan, Jennifer J O'Rourke, Dave R Praharaj & Dean W Felsher. (2013) Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opinion on Investigational Drugs 22:11, pages 1495-1509.
Read now
Read now
Roberto Ciarcia, Sara Damiano, Serena Montagnaro, Ugo Pagnini, Antonio Ruocco, Giuseppe Caparrotti, Danila d'Angelo, Silvia Boffo, Fátima Morales, Flavio Rizzolio, Salvatore Florio & Antonio Giordano. (2013) Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. Cell Cycle 12:17, pages 2839-2848.
Read now
Read now
Håkon Reikvam, Ina Nepstad, André Sulen, Bjørn Tore Gjertsen, Kimberley Joanne Hatfield & Øystein Bruserud. (2013) Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs 22:5, pages 551-563.
Read now
Read now
Øystein Bruserud & Håkon Reikvam. (2010) Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia – the biological heterogeneity. Expert Opinion on Therapeutic Targets 14:11, pages 1139-1142.
Read now
Read now
Alberto M Martelli, Camilla Evangelisti, Francesca Chiarini, Cecilia Grimaldi, Lucia Manzoli & James A McCubrey. (2009) Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opinion on Investigational Drugs 18:9, pages 1333-1349.
Read now
Read now
Articles from other publishers (24)
Chengbin Yang, Yi Chen, Tianze Wu, Yunjian Gao, Xiaofeng Liu, Yongtai Yang, Yun Ling, Yu Jia, Mingli Deng, Jianxin Wang & Yaming Zhou. (2023) Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia. European Journal of Medicinal Chemistry 258, pages 115543.
Crossref
Crossref
Xin Zhao, Huan-qiu Liu, Li-na Wang, Le Yang & Xiao-liang Liu. (2022) Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities. Seminars in Cancer Biology 83, pages 121-135.
Crossref
Crossref
Håkon Reikvam, Elise Aasebø, Annette K. Brenner, Sushma Bartaula-Brevik, Ida Sofie Grønningsæter, Rakel Brendsdal Forthun, Randi Hovland & Øystein Bruserud. (2019) High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype. Journal of Clinical Medicine 8:7, pages 970.
Crossref
Crossref
Håkon Reikvam, Randi Hovland, Rakel Brendsdal Forthun, Sigrid Erdal, Bjørn Tore Gjertsen, Hanne Fredly & Øystein Bruserud. (2017) Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer 17:1.
Crossref
Crossref
Ethan Dmitrovsky & Michael Spinella. 2017. Cancer Therapeutic Targets. Cancer Therapeutic Targets
1039
1046
.
Yalin Wang, Yan Jiang, Cuicui Bian, Yi Dong, Chao Ma, Xiaolin Hu & Ziling Liu. (2015) Overexpression of Hiwi Inhibits the Cell Growth of Chronic Myeloid Leukemia K562 Cells and Enhances Their Chemosensitivity to Daunomycin. Cell Biochemistry and Biophysics 73:1, pages 129-135.
Crossref
Crossref
N Sandhöfer, K H Metzeler, M Rothenberg, T Herold, S Tiedt, V Groiß, M Carlet, G Walter, T Hinrichsen, O Wachter, M Grunert, S Schneider, M Subklewe, A Dufour, S Fröhling, H-G Klein, W Hiddemann, I Jeremias & K Spiekermann. (2014) Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia 29:4, pages 828-838.
Crossref
Crossref
Håkon Reikvam, Jerome Tamburini, Silje Skrede, Rita Holdhus, Laury Poulain, Elisabeth Ersvaer, Kimberley J. Hatfield & Øystein Bruserud. (2014) Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. British Journal of Haematology 164:2, pages 200-211.
Crossref
Crossref
C.L. Goolsby & W.P. Hansen. 2014. Pathobiology of Human Disease. Pathobiology of Human Disease
3629
3641
.
Giliane Zanchett & Eduardo Oliveira-Filho. (2013) Cyanobacteria and Cyanotoxins: From Impacts on Aquatic Ecosystems and Human Health to Anticarcinogenic Effects. Toxins 5:10, pages 1896-1917.
Crossref
Crossref
Håkon Reikvam, Ina Nepstad, Øystein Bruserud & Kimberley Joanne Hatfield. (2013) Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget 4:6, pages 830-843.
Crossref
Crossref
Ethan Dmitrovsky & Michael Spinella. 2016. Cancer Therapeutic Targets. Cancer Therapeutic Targets
1
8
.
Anita Ryningen, Håkon Reikvam, Ina Nepstad, Kristin Paulsen Rye & Øystein Bruserud. (2012)
Inhibition of Mammalian Target of Rapamycin in Human Acute Myeloid Leukemia Cells Has Diverse Effects That Depend on the Environmental
In Vitro
Stress
. Bone Marrow Research 2012, pages 1-10.
Crossref
Crossref
A Eriksson, M Hermanson, M Wickström, E Lindhagen, C Ekholm, A Jenmalm Jensen, A Löthgren, F Lehmann, R Larsson, V Parrow & M Höglund. (2012) The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. Blood Cancer Journal 2:8, pages e81-e81.
Crossref
Crossref
Hanne Fredly, Håkon Reikvam, Bjørn Tore Gjertsen & Øystein Bruserud. (2012) Disease‐stabilizing treatment with all‐trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti‐leukemic treatment. American Journal of Hematology 87:4, pages 368-376.
Crossref
Crossref
Elisabeth Ersvaer, Kimberley J. Hatfield, Håkon Reikvam & Øystein Bruserud. (2011) Future Perspectives: Therapeutic Targeting of Notch Signalling May Become a Strategy in Patients Receiving Stem Cell Transplantation for Hematologic Malignancies. Bone Marrow Research 2011, pages 1-15.
Crossref
Crossref
James MarvinSuchitra Swaminathan, Geoffrey KrakerAmy ChadburnJames Jacobberger & Charles Goolsby. (2011) Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. Blood 117:15, pages e120-e130.
Crossref
Crossref
Katarina M. Jørgensen, Sigrun M. Hjelle, Ola K. Øye, Pål Puntervoll, Håkon Reikvam, Jørn Skavland, Endre Anderssen, Øystein Bruserud & Bjørn Tore Gjertsen. (2011) Untangling the intracellular signalling network in cancer — A strategy for data integration in acute myeloid leukaemia. Journal of Proteomics 74:3, pages 269-281.
Crossref
Crossref
J Skavland, K M Jørgensen, K Hadziavdic, R Hovland, I Jonassen, Ø Bruserud & B T Gjertsen. (2011) Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal 1:2, pages e4-e4.
Crossref
Crossref
Felicetto Ferrara, Salvatore Palmieri, Tiziana Izzo, Clelia Criscuolo & Cira Riccardi. (2010) Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome. Hematological Oncology 28:4, pages 202-208.
Crossref
Crossref
Linn Oftedal, Frode Selheim, Matti Wahlsten, Kaarina Sivonen, Stein Ove Døskeland & Lars Herfindal. (2010) Marine Benthic Cyanobacteria Contain Apoptosis-Inducing Activity Synergizing with Daunorubicin to Kill Leukemia Cells, but not Cardiomyocytes. Marine Drugs 8:10, pages 2659-2672.
Crossref
Crossref
Alberto M. Martelli, Camilla Evangelisti, Francesca Chiarini & James A. McCubrey. (2010) The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1:2, pages 89-103.
Crossref
Crossref
Barbara C. Potts & Kin S. Lam. (2010) Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides. Marine Drugs 8:4, pages 835-880.
Crossref
Crossref
Tadeusz Robak & Agnieszka Wierzbowska. (2009) Current and emerging therapies for acute myeloid leukemia. Clinical Therapeutics 31, pages 2349-2370.
Crossref
Crossref